# Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

> **NCT03569514** · — · NOT_YET_RECRUITING · sponsor: **Emergent BioSolutions** · enrollment: 10 (estimated)

## Conditions studied

- Anthrax

## Interventions

- **DRUG:** AIGIV

## Key facts

- **NCT ID:** NCT03569514
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569514, "Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03569514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*